Altamira Therapeutics Ltd. (CYTO)

Altamira Therapeutics Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	0.62	0.62	0.02	0.98	11.26	1.38
Cash & Cash Equivalents	0.62	0.62	0.02	0.98	11.26	1.38
Cash Growth	-37.27%	3910.45%	-98.44%	-91.26%	713.08%	-74.32%
Receivables	0.07	0.07	0.76	0.69	0.08	0.36
Inventory	0	0	0.01	0.84	0	0
Other Current Assets	0.53	0.53	0.98	1.58	0.28	0.63
Total Current Assets	1.22	1.22	1.77	4.09	11.62	2.37
Property, Plant & Equipment	0.08	0.08	0.45	0.56	0.05	0.07
Long-Term Investments	2.42	2.42	0	0	0	0
Goodwill and Intangibles	3.89	3.89	3.89	14.31	9.12	6.77
Other Long-Term Assets	0.08	0.08	0.19	0.2	0.02	0.02
Total Long-Term Assets	6.47	6.47	4.53	15.08	9.18	6.85
Total Assets	7.69	7.69	6.3	19.17	20.8	9.23
Accounts Payable	0.44	0.44	4.91	3.7	0.76	0.94
Deferred Revenue	0	0	0.93	0	0	0
Current Debt	0.1	0.1	5.99	0.11	0.52	0
Other Current Liabilities	0.35	0.35	1.05	1.05	1.74	1.34
Total Current Liabilities	0.89	0.89	12.88	4.86	3.03	2.28
Long-Term Debt	0	0	0.34	0.46	0	0
Other Long-Term Liabilities	0.35	0.35	1.39	0.81	1	0.91
Total Long-Term Liabilities	0.35	0.35	1.74	1.27	1	0.91
Total Liabilities	1.24	1.24	14.62	6.13	4.03	3.19
Total Debt	0.1	0.1	6.33	0.58	0.52	0
Debt Growth	-82.69%	-98.43%	999.68%	9.89%	-	-
Retained Earnings	-18.05	-18.05	-201.43	-175.69	-160.64	-152.78
Comprehensive Income	0	0	0	0.06	0.06	-0.03
Shareholders' Equity	6.46	6.46	-8.31	13.04	16.77	6.04
Net Cash / Debt	0.52	0.52	-6.32	0.41	10.73	1.38
Net Cash / Debt Growth	26.76%	-	-	-96.20%	675.24%	-65.01%
Working Capital	0.33	0.33	-11.11	-0.77	8.59	0.1
Book Value Per Share	16.24	16.24	-194.91	382.21	1325.92	1287.85

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).